John Lund, MD
Cardiovascular Disease · Ogden, UTNPI 1477578557
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Biosense Webster, Inc. at 38.4% of the total. Reporting peaked in 2022 at $360 and has fallen 68.0% since, to $115 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in UT, where the typical reported total is $1,352.
Across 33 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$336
- Medtronic$274
- Boston Scientific$120
- Novartis$51
- Abbott$41
- Biotronik Inc.$24
- plus $29 from 2 others
Across 4 payments — averaging $406.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$2K
What the payments were for
- Food & beverage$874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 12 | $336 |
| Medtronic(2 entities) | 10 | $274 |
| Boston Scientific | 3 | $120 |
| Novartis | 3 | $51 |
| Abbott | 2 | $41 |
| Biotronik Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
How this compares
$874 in reported general payments places this provider in the 40th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $105,294 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 49 | $922 |
| Flecainide Acetate | 25 | $859 |
| Metoprolol Succinate | 38 | $785 |
| Sodium Chloride0.9 % Sodium Chloride | 17 | $416 |
| Amiodarone Hcl | 24 | $233 |
| Carvedilol | 14 | $168 |
| Minocycline Hcl | 32 | $163 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Ogden
- Saima HusainOgden$4K
- Shane RuckelOgden$2K
- Sergio ColladoOgden$2K
- Michael BuchOgden$2K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.